No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following ...

Avinasi Labs Enables a New Funding & Revenue Model for Clinical Stage Assets via DeLong Protocol SAN FRANCISCO, CA, UNITED STATES, December 31, 2025 /EINPresswire.com/ — Avinasi Labs, an AI-native ...

FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures ...

Silo Pharma, Inc. (Nasdaq: SILO) ("Silo” or the "Company”), a diversified developmental stage biopharmaceutical and ...

The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial guidance, the company said. ・Genmab assumed sole responsibility for the ...

Genmab (GMAB) will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab’s strategic focus on the most ...

Over the past decade, a shift has been occurring in biopharma R&D. Despite great advancements in drug technologies and our understanding of diseases, it is getting harder to develop new drugs and ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

The FDA’s emerging framework represents more than a regulatory update; it is a paradigm shift toward human-relevant, ...

AI’s true promise is turning clinical development from a bottleneck into a throughput engine for human health. Drug discovery ...

Advances in our understanding of cancer biology have led to the discovery of a spectrum of new therapeutic targets. However, despite remarkable progress in the identification and characterization of ...